vTv Therapeutics Inc. (VTVT)
19.66
1.26 (6.85%)
At close: Feb 28, 2025, 3:53 PM
19.66
0.00%
After-hours: Feb 28, 2025, 03:53 PM EST
No 1D chart data available
| Bid | 14.75 |
| Market Cap | 51.36M |
| Revenue (ttm) | 474.45K |
| Net Income (ttm) | -8.76M |
| EPS (ttm) | -4.37 |
| PE Ratio (ttm) | -4.5 |
| Forward PE | -2.98 |
| Analyst | Buy |
| Ask | 22.72 |
| Volume | 15,589 |
| Avg. Volume (20D) | 15,058 |
| Open | 18.40 |
| Previous Close | 18.40 |
| Day's Range | 17.09 - 19.66 |
| 52-Week Range | 12.12 - 30.99 |
| Beta | 0.72 |
About VTVT
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is a...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2015
Employees 16
Stock Exchange NASDAQ
Ticker Symbol VTVT
Website https://www.vtvtherapeutics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 78.03% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
7 months ago
-24.53%
vTv Therapeutics shares are trading lower after th...
Unlock content with
Pro Subscription
7 months ago
+0.9%
vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.
1 year ago · pennystocks.com
Best Penny Stocks To Buy Under $1? 4 To Watch NowFinding the best penny stocks to buy seems easy.